Mumbai-based nutrition brand TruNativ has raised $30 million in a Series B funding round led by global healthcare investor OrbiMed. This capital injection will fuel the company's mission to make science-backed, clean nutrition accessible across India. The investment underscores the growing importance of preventive healthcare and everyday wellness solutions for consumers.
Strategic Capital for Nationwide Expansion
TruNativ will allocate the new funds to significantly broaden its distribution network across the country. The company plans to expand its offline retail presence in Tier I and II cities by partnering with major supermarket chains. This move is part of a larger strategy to make its products readily available to a wider audience.
Beyond traditional retail, the company is targeting the hotel, restaurant, and catering (HORECA) sector for growth. It aims to place its supplements and sugar replacements in hotel rooms, conference venues, and on restaurant menus. This initiative seeks to integrate healthy nutrition options seamlessly into consumers' daily routines.
Fostering Innovation and Product Development
A key part of the expansion includes launching a new innovation center in Mumbai, named The Good Lab. This facility will serve as the hub for the company's research and development to enhance its supplement offerings. It will also support the development of new products, including upcoming vitamin-based supplements.
The company also intends to scale its B2B2C ingredient business, which provides nutrition solutions to other consumer brands. Through its Mark of Good program, partners can leverage TruNativ's technical expertise and R&D lab. This B2B focus aims to fortify a wider range of products with high-quality protein.
Investor Confidence and Market Dynamics
The Series B round comprised both a primary investment and secondary share sales, facilitating an exit for early investors like 100Unicorns. Meanwhile, existing stakeholder Emami diluted its holding from 19% to 10%, signaling a strategic shift. The transaction highlights strong investor confidence in TruNativ's growth trajectory and market potential.
With this investment, Dr. Sunny Sharma and Sumona Chakraborty of OrbiMed will join TruNativ's board of directors. Their inclusion is expected to provide valuable strategic guidance as the company navigates its next growth phase. OrbiMed's backing validates the view that preventive nutrition is becoming a healthcare imperative in India.
Impressive Growth in a Competitive Market
Founded in 2019 by Pranav and Mamta Malhotra, TruNativ has shown remarkable financial performance. The company reported revenues of ₹130 crore for fiscal year 2026 and is targeting ₹200 crore this year. This rapid growth reflects the increasing consumer demand for accessible and trustworthy nutrition products.
TruNativ operates within a highly competitive nutraceutical market, fueled by rising health awareness and disposable incomes. The brand competes with several others for a share of the market, which is seeing increased interest in everyday protein supplements. The Indian protein supplement market is projected to exceed $1.5 billion by 2033.
This $30 million funding round positions TruNativ to accelerate its growth and solidify its leadership in India's nutrition sector. By expanding distribution, investing in innovation, and strengthening B2B partnerships, the company is poised to capitalize on the shift towards preventive health. The investment from a firm like OrbiMed marks a significant milestone in TruNativ's journey.